Millennium Management
CMMB

Millennium Management’s Chemomab Therapeutics CMMB Stock Holding History

Millennium Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,641
Closed -$16.6K – 6017
2024
Q3 		$16.6K Buy
+2,641
New +$14.8K ﹤0.01% 5815
2024
Q1 		– Sell
-4,925
Closed -$10K – 6230
2023
Q4 		$10K Buy
+4,925
New +$13K ﹤0.01% 5740

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Millennium Management's CMMB Position: Q4 2024 in Review

Millennium Management sold out of Chemomab Therapeutics (CMMB) in Q4 2024, closing a stake of 2,641 shares — an estimated $16.6K sold.

Millennium Management first reported a position in CMMB in Q4 2023 and held it in 2 quarters. The position peaked at $16.6K in Q3 2024. 16 funds tracked by Wall St. Rank hold CMMB as of Q4 2024.

  • Millennium Management reported no remaining Chemomab Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Millennium Management sold 2,641 Chemomab Therapeutics shares in Q4 2024, an estimated $16.6K.
  • Millennium Management first reported a position in Chemomab Therapeutics in Q4 2023 and held it in 2 quarters.
  • Millennium Management's Chemomab Therapeutics position peaked at $16.6K in Q3 2024.
  • 16 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q4 2024.

Based on Millennium Management's 13F filing for Q4 2024, filed 14 Feb 2025.